Source link : https://www.newshealth.biz/health-news/neoadjuvant-pd-1-blockade-boosts-pcr-rates-in-early-esophageal-cancer/
SAN FRANCISCO — Adding an investigational PD-1 inhibitor to chemotherapy in the neoadjuvant setting significantly improved pathological complete response (pCR) rates for patients with resectable locally advanced esophageal squamous cell carcinoma (ESCC), a randomized phase III trial from China showed. In an intention-to-treat population, treatment with camrelizumab plus paclitaxel and cisplatin resulted in a pCR […]
Author : News Health
Publish date : 2024-01-22 14:19:06
Copyright for syndicated content belongs to the linked Source.